Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
about
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase II study of paclitaxel a ...... epithelial ovarian carcinoma.
@en
Phase II study of paclitaxel associated with lipid core nanoparticles
@nl
type
label
Phase II study of paclitaxel a ...... epithelial ovarian carcinoma.
@en
Phase II study of paclitaxel associated with lipid core nanoparticles
@nl
prefLabel
Phase II study of paclitaxel a ...... epithelial ovarian carcinoma.
@en
Phase II study of paclitaxel associated with lipid core nanoparticles
@nl
P2093
P2860
P1433
P1476
Phase II study of paclitaxel a ...... epithelial ovarian carcinoma.
@en
P2093
Aleksandra T Morikawa
Brigitte M Van Eyll
Carolina G Vital
Hezio J Fernandes Junior
Raul C Maranhão
Roberto Kalil Filho
Silvia R Graziani
P2860
P2888
P356
10.1007/S12032-017-1009-Z
P577
2017-07-29T00:00:00Z